• November 28, 2012

    Sagent Pharmaceuticals Announces Launch of Nafcillin for Injection, USP.

    Sagent Pharmaceuticals, Inc. today announced the launch of Nafcillin for Injection, USP, in two vial presentations and one pharmacy bulk package bottle; all three are latex-free and preservative-free. According to IMS, for the 12 months ending September 2012, the US market for Nafcillin approximated $62 million. As with all products in Sagent's portfolio, Nafcillin features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

    Nafcillin for Injection, USP is a semisynthetic penicillin indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. It may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. It should not be used in infections caused by organisms susceptible to penicillin G.

  • September 4, 2012

    Astral Pharmaceutical Industries is now Astral SteriTech Private Limited.

    We are pleased to announce that Astral Pharmaceutical Industries has been rechristened as ASTRAL STERITECH PRIVATE LIMITED and the Certificate of Incorporation from Registrar of Companies to this effect has been received.

    The change in name is envisaged to emphasize on the core competence and niche activities of the firm i.e. sterile manufacturing with state of the art technology orientation.

    We are now in the process of registering this change with various statutory bodies/authorities.

  • August 24, 2012

    Astral Pharmaceutical is granted approval for Nafcilin for injection by FDA.

    Astral Pharmaceutical Industries has been granted approval for Naficilin for injection USP 1G, 2G and 10G.

  • July 24, 2012

    Launch of Oxcaillin for injection for the US market.

    Sagent Pharmaceuticals, Inc. today announced the launch of Oxacillin for Injection, USP, in three latex-free, preservative-free vial presentations. According to IMS data for the twelve-months ended May 2012, the U.S. market for Oxacillin approximated $29 million. As with all products in Sagent's portfolio, Oxacillin features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.

    Oxacillin for Injection, USP is a semisynthetic penicillin indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug.

  • March 31, 2012

    Sagent in collaboration with ASTRAL is granted approval for Oxacillin for Injection, USP 1g and 2g vials and Oxacillin for Injection, USP 10 g - Pharmacy Bulk products, by US FDA.

    Sagent USA has filed several ANDAs with ASTRAL. This is the first ANDA approval from our site and several more are expected in near future.
    The latest US FDA inspection at ASTRAL was comprehensively successful. There were no audit observations i.e. without any 483's.
    ASTRAL is expected to launch the Oxacillin range of products to US market during Q2 of 2012.

  • April 20, 2010

    Subsequent to the US FDAs Pre Approval Inspection in January 2010, our both facilities Semi Synthetic Penicillins (SSP) & Cephalosporins, are accepted by CDER, FDA to manufacture the products for US market.

  • November 27, 2007

    Sagent Pharmaceuticals Inc. and Astral Pharmaceutical Industries Announce Collaboration for Developing and Manufacturing Injectable Antibiotics. 27th November, 2007.

    SCHAUMBURG, Ill., Nov. 27 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, and Astral Pharmaceutical Industries, a global pharmaceutical manufacturing company located in India, today announced an agreement in which Astral will develop, manufacture and supply injectable products for which Sagent will obtain U.S. regulatory approval and market in the United States.

    "Sagent is committed to establishing strategic partnerships that provide the most diverse and extensive pipeline for our hospital-focused customers," said Jeffrey M. Yordon, CEO, founder and chairman of the board of Sagent Pharmaceuticals, Inc. "We are thrilled to have the opportunity to partner with Dr. Patel and Astral, a leading, worldwide manufacturer of much needed antibiotic injectable products. This partnership in a key therapeutic category strongly positions Sagent in our target markets."

    "Astral is rapidly establishing a global footprint," said Dushyant R. Patel, CEO, Astral Pharmaceutical Industries. "Collaborating with a partner of Sagent's caliber in the United States is a fantastic opportunity for Astral to quickly expand our science, quality and manufacturing expertise in injectable anti-infectives to the U.S. market."

    About Sagent Pharmaceuticals, Inc.
    Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific focus on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.
    For more information about Sagent, please visit

    About Astral Pharmaceutical Industries
    Astral Pharmaceutical Industries, located in Vadodara, India, is an exclusive state-of-the-art manufacturing company specializing in sterile antibiotic powder injectables. Founded in 1991, Astral was the first Indian company to develop indigenous technology to manufacture sterile amoxicillin sodium and has subsequently integrated into production of sterile antibiotic powder formulations. Astral has independent and dedicated facilities to manufacture injectable formulations for cephalosporin and penicillin products.
    For more information about Astral, please visit

    SOURCE Sagent Pharmaceuticals, Inc.